Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of claims:

1-10 (canceled)

11. (Original) A method of treating, inhibiting or controlling a ras-associated disease by inhibiting farnesyl-protein transferase(FPTase) enzyme in a mammal in need thereof, which comprises administering to said mammal an effective amount of a compound of Formula (I)



Formula (I)

wherein:

R_1 is a moiety



;

R_2 is a moiety



;

n is an integer of 1 and 3 to 9;
m is an integer of 0 or 2;
R_3 and R_4 are independently selected from the group consisting of hydrogen, alkyl of 1 to 10 carbon atoms, alkoxy of 1 to 10 carbon atoms, halogen, nitro, trifluoromethoxy, phenoxy optionally mono or di substituted, and benzyloxy optionally mono or di substituted;

R_5, and R_6, are independently selected from the group consisting of hydrogen, alkyl of 1 to 10 carbon atoms, halogen, nitro, phenyl optionally mono or di-substituted, phenoxy optionally mono or di-substituted, trifluoromethyl, trifluoromethoxy, and methanesulphonyl;

or a pharmaceutically acceptable salt thereof.

12. (Original) The method according to claim 11 wherein R_1 is 4-methoxyphenyl and R_2 is 4-chlorophenyl or a pharmaceutically acceptable salt thereof.

13. (Original) The method according to claim 11 wherein n is 3 and m is 2 or a pharmaceutically acceptable salt thereof.

14. (Original) The method according to claim 11, where the compound is 3-[5-(4-Chlorophenyl)pent-4-ynyl]-3-(4-methoxybenzenesulfonyl)pyrrolidine-2,5-dione or a pharmaceutically acceptable salt thereof.

15. (Original) The method according to claim 11, where the compound is 13-[3-(4-Chlorophenyl)prop-2-ynyl]-3-(4-methylbenzenesulfonyl)- pyrrolidine-2,5-dione or a pharmaceutically acceptable salt thereof.

16. (Original) The method of Claim 11 wherein the ras-associated disease in mammals is selected from the group consisting of cancers of the pancreas, breast,

lung, colon, epidermis, prostate, bladder, thyroid,myelodysplastic tumors and myeloid leukemia.

17. (Original) The method of Claim 11 wherein the ras-associated disease in mammals is selected from metastasis, suppressing angiogenesis, and inducing apoptosis.

18. (Original) The method of Claim 11 wherein the ras-associated proliferative disease in mammals is restenosis, neurofibromatosis, endometriosis, and psoriasis.

19. (Original) The method of Claim 11 wherein the ras-associated disease in mammals is prenyl modifications or proteins.

20-25 (canceled).